Cargando…
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
BACKGROUND: To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). METHODS: RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramuc...
Autores principales: | Necchi, Andrea, Nishiyama, Hiroyuki, Matsubara, Nobuaki, Lee, Jae-Lyun, Petrylak, Daniel P., de Wit, Ronald, Drakaki, Alexandra, Liepa, Astra M., Mao, Huzhang, Bell-McGuinn, Katherine, Powles, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648381/ https://www.ncbi.nlm.nih.gov/pubmed/33160359 http://dx.doi.org/10.1186/s12894-020-00752-w |
Ejemplares similares
-
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
por: de Wit, Ronald, et al.
Publicado: (2022) -
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
por: van der Heijden, Michiel S., et al.
Publicado: (2022) -
Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018) -
Apatorsen plus docetaxel versus docetaxel alone in
platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)